Tim Doyle

Like, I think that's pretty obvious and yeah, it made no sense along the way.

And, but what they did that I thought was really clever that like, you know, hopefully there are analogous things in eucalyptus, which is like, they ate the gross margin of categories when it appeared.

And we did that as well.

Often the tension with building a more durable business, we like stopped and picked up the gross margin dollar where it was every time.

And that's kind of the reason we're as big as we were.

I mean, the last five years, it has been better to be a holder of Eli Lilly, of course.

The drug pipeline has been...

Phenomenal.

I would say that doesn't necessarily hold true for the next five years.

I would say my couple of views are Novo has figured out how to launch a consumer drug, and that's evident in the Wagovi pill, and they have an advantage in the pill, so there's something for them there, which is good news for them.

On the pipeline side, I think Red or True Tide is overhyped.

I think...

Manjaro or Tezapatide is nearly the perfect drug in the sense that it has incredible weight loss, a very manageable side effect profile and is extremely successful.

So I guess like how many people do you know need to lose 35% of their body weight?

Fair.

And then I guess the other question... How many people want to lose 35% of their body weight?

Not very many.

Yeah, that's fair.

That's actually a lot.

And so kind of if you read the paper, the side effect profile is like reasonably far worse than Manjaro.